Dr Elise Sullivan joins LeafCann Research

Medicinal cannabis start-up LeafCann Research and Advisory has appointed Dr Elise Sullivan as its director of clinical education.

Dr Elise Sullivan, PhD, FACN, GAICD, Grad Dip Bus M, Dip Health (RN), Cert IV T&A, will advance the development of medicinal cannabis clinical education for LeafCann Research and Advisory, and liaise with state and federal government. She is the founder of the Australian College of Clinical Research, a registered training organisation offering certificate- and diploma-level qualifications.

“We are thrilled to have attracted Dr Elise Sullivan to our core team of experts. Her experience in advancing legislation for scheduled substances and her passion and expertise in clinical education and leadership are central to advancing our global education footprint,” said LeafCann Group CEO Dr Jaroslav Boublik.

The global medical cannabis industry is estimated to reach $50 billion by 2025.

LeafCann Research and Advisory recently signed a global agreement with iCAN: Israel to create iCAN: Australia, to transfer clinical trial and formulation IP from Israel to Australia and participate in a number of multicentre clinical trials, and appointed Leah Bisiani as director of clinical research.

LeafCann Research and Advisory’s Clinical Education Program will be incorporated into iCAN’s product offerings and distributed via iCAN’s global reach. In addition, iCAN: Australia will take a significant interest in CannaTech Australia, the country’s first major Medical Cannabis Summit modelled after the highly successful CannaTech Israel Summits. The first CannaTech Australia conference will take place in Sydney in 2018 and will have strong education and industry focus.